Livzon Pharma to acquire 64.81% stake in Vietnam's IMP

Livzon Pharmaceutical Group Co., Ltd. announced that its wholly-owned subsidiary, LIAN SGP HOLDING PTE. LTD., has entered into an agreement to acquire 64.81% of the shares of Imexpharm Corporation (IMP), a publicly listed Vietnamese pharmaceutical company. The deal, valued at VND 5,730,815,426,000 (approximately CNY 15.87 billion), will be executed through the purchase of shares from SK Investment Vina III Pte. Ltd., Sunrise Kim Investment Joint Stock Company, and KBA Investment Joint Stock Company. IMP is a prominent Vietnamese pharmaceutical firm focusing on research, production, and sales of drugs, including antibiotics and cardiovascular medications. The acquisition remains subject to regulatory approvals and customary closing conditions. Post-acquisition, IMP will become a consolidated subsidiary of Livzon Pharma.